Healthcare Industry News: BD
News Release - March 13, 2013
BD Announces Appointment of Dr. Ellen Strahlman as Chief Medical Officer and Senior Vice President, Research & DevelopmentFRANKLIN LAKES, N.J., March 13, 2013 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced the appointment of Ellen Strahlman, M.D., M.H.Sc., to the newly created position of Chief Medical Officer and Senior Vice President, Research & Development, effective April 22, 2013. Dr. Strahlman will report to Chairman, CEO and President Vincent A. Forlenza and will serve as a member of the Company's Management Committee and Leadership Team. In her new role, Dr. Strahlman will oversee the Company's Medical Affairs and Research & Development functions.
"I am very pleased that Dr. Strahlman will be joining BD at a time when we are strategically focused on driving growth through innovation and customer focus," said Mr. Forlenza. "She brings extensive experience as a senior physician and leader in the pharmaceutical and medical device industries, and her patient-centric approach aligns with our focus on providing innovative solutions to address the healthcare needs of customers and patients."
Dr. Strahlman joins BD from GlaxoSmithKline, where she served as Senior Vice President and Chief Medical Officer since 2008 and more recently worked in the Office of the CEO as Senior Medical Advisor and Global Head of Neglected Tropical Diseases. As GSK's Chief Medical Officer, Dr. Strahlman had accountability for safety and patient matters for all programs in development and commercialized products in the Vaccines, Pharmaceutical and Consumer businesses, as well as organizational responsibility for medical affairs, regulatory affairs, clinical safety and other areas. Prior to GlaxoSmithKline, Dr. Strahlman has held executive leadership roles at Merck, Novartis, Pfizer, and Bausch & Lomb that included oversight of the development and commercialization of proprietary and generic pharmaceuticals, drug delivery systems and medical devices.
Dr. Strahlman obtained her M.D. from the Johns Hopkins University School of Medicine, her M.H.Sc. from the Johns Hopkins School of Public Health and her B.A. degree from Harvard University.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
Source: Becton, Dickinson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.